Regeneron ONYX AMD-1517

Completed Studies

A randomized, double masked, active controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients with Neovascular AMD.

Duration: 36 weeks

 

 

This entry was posted in Uncategorized. Bookmark the permalink.